Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.
The Zhitong Finance App learned that on May 14, 2024, Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel to treat recurrent or refractory multiple myeloma on the ClinicalTrials.gov website. This phase III clinical trial will begin in October this year. It is planned to enroll 450 patients with recurrent or refractory multiple myeloma. It is expected to be initially completed in 2028.
On May 9, ArcellX announced the experimental design plan for this phase III clinical Immagine-3. 450 patients were randomly grouped 1:1 to receive Anito-cel treatment or standard treatment plan. In collaboration with Gilead, Kite's advanced production process can be used. Key clinical IMMagine-1 treatment with anito-cel is ongoing, and it is expected that the latest data will be released before the end of this year. This time, a phase III verification clinical trial of previous treatment has been initiated.